3138 Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis

• Nevin John,
• Tomas Kalincik,
• Jeannette Lechner-Scott,
• Suzanne Hodgkinson,
• Helmut Butzkueven,
• Michael Barnett,
• Anneke Van Der Walt,
• Izanne Roos,
• Charles Malpas,
• Katherine Buzzard,
• Olga Skibina,
• Sifat Sharmin

Affiliations

Nevin John

Queen Square MS Centre, Department of Neuroinflammation, UCL Institute of Neurology, London, UK

Tomas Kalincik

CORe, Department of Medicine, University of Melbourne, Parkville, Victoria, Australia

Jeannette Lechner-Scott

27 University of Newcastle Hunter Medical Research Institute, Newcastle, New South Wales, Australia

Suzanne Hodgkinson

9Liverpool Hospital, Liverpool, NSW, Australia

Helmut Butzkueven

Clinical Neurosciences, Alfred Health, Melbourne, Victoria, Australia

Michael Barnett

1Royal Prince Alfred Hospital, Camperdown, NSW, Australia

Anneke Van Der Walt

3Department of Neurosciences, Monash University, Prahran, VIC, Australia

Izanne Roos

CORe, Department of Medicine, University of Melbourne, Parkville, Victoria, Australia

Charles Malpas

1 Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia

Katherine Buzzard

4 Eastern Health, Box Hill, Victoria, Australia

Olga Skibina

Clinical Neurosciences, Alfred Health, Melbourne, Victoria, Australia

Sifat Sharmin

CORe, Department of Medicine, University of Melbourne, Parkville, Victoria, Australia